Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Robert Mayo who wrote (257)	8/28/1998 1:01:00 PM
From: John Patterson	Respond to of 712

H&Q also reissued a "Strong Buy" yesterday.

To: Robert Mayo who wrote (257)	9/29/1998 10:20:00 PM
From: Robert Mayo	Read Replies (1) \| Respond to of 712

FYI: Cor Therapeutics Down 17% Following H&Q Downgrade Dow Jones Newswires NEW YORK -- Shares of Cor Therapeutics Inc. were off as much as 21.7% to a new 52-week low Tuesday after Hambrecht & Quist LLC, citing the slow roll-out of the company's Intergrilin drug, downgraded the stock to buy from strong buy. The company's shares were recently down 1 1/2, or 15.8%, at 8, after having been as low as 7 7/16; the previous 52-week low, 8 7/16, was reached Aug. 27. Nasdaq volume, at more than 1.3 million shares, was four times the daily average of 332,460. In its research note Tuesday, Hambrecht & Quist said it was lowering its projections for sales of Integrilin to $10 million from $30 million for 1998, to $91 million from $175 million for 1999 and to $195 million from $300 million for 2000. Hambrecht & Quist also widened its loss estimate to $1.36 a share from $1.16 for 1998, and to $1.04 a share from 39 cents for 1999. It did add, though, that it still believes Integrilin "will emerge as a key therapeutic" in the management of acute coronary syndromes - it will just take longer than previously expected to grow the market. Cor Therapeutics could not immediately be reached for comment. ##### ###### Not good.